...
首页> 外文期刊>Nature reviews Drug discovery >Intravitreal injection of conbercept combined with retinal photocoagulation on macular edema secondary to branch retinal vein occlusion
【24h】

Intravitreal injection of conbercept combined with retinal photocoagulation on macular edema secondary to branch retinal vein occlusion

机译:玻璃体内注射Conbercept结合视网膜光凝聚对次级静脉静脉闭塞的黄斑水肿

获取原文
获取原文并翻译 | 示例
           

摘要

Effects of Conbercept combined with retinal photocoagulation on macular edema secondary to branch retinal vein occlusion (BRVO) were investigated. A total of 98 patients (98 eyes) with macular edema secondary to BRVO were collected. The central macular thickness (CMT), incidence rate of complications after treatment and best corrected visual acuity (BCVA) were recorded. Also the factors affecting visual recovery of patients were analyzed. At 1 week, 1 month, 3 months and 6 months after treatment, the BCVA in both groups was significantly superior to that before treatment (P<0.05). In the combination group and laser group, the logarithm of the minimum angle of resolution (logMAR) of BCVA increased from 0.84 +/- 0.47 to 0.34 +/- 0.10 and from 0.89 +/- 0.49 to 0.45 +/- 0.14, and CMT declined from 559.5 +/- 152.7 to 267.8 +/- 19.8 mu m and from 570.3 +/- 172.6 to 314.7 +/- 18.4 mu m. It was observed that at 1 week, 1 month, 3 months and 6 months after treatment, the BCVA in combination group was obviously better than that in laser group (P=0.008, P<0.001, P=0.004, P<0.001, respectively), while CMT in combination group was obviously smaller than that in laser group (P=0.009, P=0.002, P<0.001, P<0.001). Conbercept with retinal photocoagulation can effectively improve the visual acuity and reduce the CMT. The visual recovery of patients after treatment is related to the BCVA before treatment, decreased value of CMT at 1 month after treatment and integrity of external limiting membrane (ELM).
机译:研究了Conbercept结合视网膜光凝血对分枝视网膜静脉闭塞(BRVO)的黄斑水肿的影响。收集了共有98名患者(98只眼),次级为BRVO的黄斑水肿。记录中央黄斑厚度(CMT),治疗后并发症发病率和最佳矫正视力(BCVA)。还分析了影响患者视觉恢复的因素。治疗后1周,1个月,3个月和6个月,两组BCVA在治疗前显着优于该组(P <0.05)。在组合组和激光组中,BCVA分辨率最小角度(Logmar)的对数从0.84 +/- 0.47增加到0.34 +/- 0.10,0.89 +/- 0.49至0.45 +/- 0.14和CMT从559.5 +/-152.7达到267.8 +/- 19.8 mu m,从570.3 +/- 172.6到314.7 +/- 18.4 mu m。观察到治疗后1周,1个月,3个月和6个月,组合组中的BCVA显然比激光组(P = 0.008,P <0.001,P = 0.004,P <0.001) ),而组合组中的CMT明显小于激光组(P = 0.009,P = 0.002,P <0.001,P <0.001)。具有视网膜光凝的Conbercept可以有效地改善视力并减少CMT。治疗后患者的视觉恢复与治疗前的BCVA有关,治疗后1个月的CMT值下降,外部限制膜(ELM)的完整性降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号